These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 31497874)

  • 1. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.
    Chiang H; Lee JC; Huang HC; Huang H; Liu HK; Huang C
    Br J Pharmacol; 2020 Jan; 177(2):239-253. PubMed ID: 31497874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ugonin J improves metabolic disorder and ameliorates nonalcoholic fatty liver disease by regulating the AMPK/AKT signaling pathway.
    Chang TC; Chiou WC; Lai WH; Huang HC; Huang YL; Liu HK; Liang YC; Huang C
    Pharmacol Res; 2021 Jan; 163():105298. PubMed ID: 33220422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice.
    Lu H; Yuan X; Zhang Y; Han M; Liu S; Han K; Liang P; Cheng J
    Biomed Pharmacother; 2020 Sep; 129():110347. PubMed ID: 32535386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis.
    Chun HJ; Kim ER; Lee M; Choi DH; Kim SH; Shin E; Kim JH; Cho JW; Han DH; Cha BS; Lee YH
    Metabolism; 2023 Aug; 145():155612. PubMed ID: 37277060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COH-SR4 reduces body weight, improves glycemic control and prevents hepatic steatosis in high fat diet-induced obese mice.
    Figarola JL; Singhal P; Rahbar S; Gugiu BG; Awasthi S; Singhal SS
    PLoS One; 2013; 8(12):e83801. PubMed ID: 24376752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E
    Yoshino K; Hosooka T; Shinohara M; Aoki C; Hosokawa Y; Imamori M; Ogawa W
    Biochem Biophys Res Commun; 2021 Jun; 557():62-68. PubMed ID: 33862461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
    Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
    Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
    Gaborit B; Ancel P; Abdullah AE; Maurice F; Abdesselam I; Calen A; Soghomonian A; Houssays M; Varlet I; Eisinger M; Lasbleiz A; Peiretti F; Bornet CE; Lefur Y; Pini L; Rapacchi S; Bernard M; Resseguier N; Darmon P; Kober F; Dutour A
    Cardiovasc Diabetol; 2021 Mar; 20(1):57. PubMed ID: 33648515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
    Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
    EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway.
    Luo J; Sun P; Wang Y; Chen Y; Niu Y; Ding Y; Xu N; Zhang Y; Xie W
    Eur J Pharmacol; 2021 Sep; 907():174304. PubMed ID: 34224699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats.
    Qiu X; Gao DH; Xiang X; Xiong YF; Zhu TS; Liu LG; Sun XF; Hao LP
    World J Gastroenterol; 2015 Jul; 21(26):8061-72. PubMed ID: 26185377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
    Fu D; Cui H; Zhang Y
    Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chronic p,p'-dichlorodiphenyldichloroethylene (DDE) exposure on high fat diet-induced alterations in glucose and lipid metabolism in male C57BL/6H mice.
    Howell GE; Mulligan C; Meek E; Chambers JE
    Toxicology; 2015 Feb; 328():112-22. PubMed ID: 25541407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease.
    Wilson RB; Chen YJ; Sutherland BG; Sawyez CG; Zhang R; Woolnough T; Hetherington AM; Peters KM; Patel K; Kennelly JP; Leonard KA; Schuurman M; Jacobs RL; Wang R; Borradaile NM
    Pharmacol Res; 2020 Nov; 161():105208. PubMed ID: 32977024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The innovative "Bio-Oil Spread" prevents metabolic disorders and mediates preconditioning-like cardioprotection in rats.
    Quintieri AM; Filice E; Amelio D; Pasqua T; Lupi FR; Scavello F; Cantafio P; Rocca C; Lauria A; Penna C; De Cindio B; Cerra MC; Angelone T
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):603-613. PubMed ID: 27113292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
    Iwamoto Y; Kimura T; Dan K; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nogami Y; Shirakiya Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2024 Jun; 26(6):2339-2348. PubMed ID: 38504118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis.
    Vitaglione P; Mazzone G; Lembo V; D'Argenio G; Rossi A; Guido M; Savoia M; Salomone F; Mennella I; De Filippis F; Ercolini D; Caporaso N; Morisco F
    J Nutr Sci; 2019; 8():e15. PubMed ID: 31037218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteolin-Enriched Artichoke Leaf Extract Alleviates the Metabolic Syndrome in Mice with High-Fat Diet-Induced Obesity.
    Kwon EY; Kim SY; Choi MS
    Nutrients; 2018 Jul; 10(8):. PubMed ID: 30060507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.